Moderately Differentiated Neuroendocrine Carcinoma of the Larynx
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chung, Eun-Jae | - |
dc.contributor.author | Baek, Seung-Kuk | - |
dc.contributor.author | Kwon, Soon-Young | - |
dc.contributor.author | Woo, Jung-Soo | - |
dc.contributor.author | Jung, Kwang-Yoon | - |
dc.date.accessioned | 2021-09-09T02:10:56Z | - |
dc.date.available | 2021-09-09T02:10:56Z | - |
dc.date.created | 2021-06-10 | - |
dc.date.issued | 2008-12 | - |
dc.identifier.issn | 1976-8710 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/122339 | - |
dc.description.abstract | Neuroendocrine neoplasm of the larynx is a morphologically heterogeneous group of tumors. This unusual neoplasm includes the four different type of tumors. Paraganglioma is the best-known neural origin tumor. The epithelial origin tumor is further divided based on the degree of differentiation into well, moderately, and poorly differentiated carcinoma. The diverse biological behavior of neuroendocrine neoplasm of larynx makes an accurate diagnosis of paramount importance, since treatment depends on diagnostic accuracy. The diagnosis is based primarily on light microscopy, and immunohistochemical and/or ultrastructural investigations are needed to diagnose correctly. The mainstay of treatment of moderately differentiated neuroendocrine carcinoma of the larynx is surgery. Elective neck treatment should be performed considering the high likelihood of cervical lymph node metastases. The 5-yr survival rate approximates 50%, and 10-yr survival rate is only 30%. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN SOC OTORHINOLARYNGOL | - |
dc.subject | NEOPLASMS | - |
dc.subject | DIAGNOSIS | - |
dc.subject | TUMORS | - |
dc.title | Moderately Differentiated Neuroendocrine Carcinoma of the Larynx | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Baek, Seung-Kuk | - |
dc.contributor.affiliatedAuthor | Kwon, Soon-Young | - |
dc.identifier.doi | 10.3342/ceo.2008.1.4.217 | - |
dc.identifier.wosid | 000265695100008 | - |
dc.identifier.bibliographicCitation | CLINICAL AND EXPERIMENTAL OTORHINOLARYNGOLOGY, v.1, no.4, pp.217 - 220 | - |
dc.relation.isPartOf | CLINICAL AND EXPERIMENTAL OTORHINOLARYNGOLOGY | - |
dc.citation.title | CLINICAL AND EXPERIMENTAL OTORHINOLARYNGOLOGY | - |
dc.citation.volume | 1 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 217 | - |
dc.citation.endPage | 220 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001354024 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.relation.journalResearchArea | Otorhinolaryngology | - |
dc.relation.journalWebOfScienceCategory | Otorhinolaryngology | - |
dc.subject.keywordPlus | NEOPLASMS | - |
dc.subject.keywordPlus | DIAGNOSIS | - |
dc.subject.keywordPlus | TUMORS | - |
dc.subject.keywordAuthor | Neuroendocrine carcinoma | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.